Pharmacological Management of Polycystic Ovary Syndrome (PCOS)

First-Line Treatments

• The American College of Obstetricians and Gynecologists recommends metformin as the cornerstone medication for PCOS, improving insulin sensitivity, reducing testosterone levels, and addressing metabolic abnormalities, though lifestyle modification with even 5% weight loss should precede or accompany pharmacotherapy 1
• Metformin improves insulin sensitivity, which reduces insulin levels and subsequently decreases ovarian androgen production, lowering testosterone levels 1
• Interventions improving insulin sensitivity may positively impact risk factors for diabetes and cardiovascular disease in women with PCOS 1
• Metformin tends to decrease weight in PCOS patients, unlike thiazolidinediones which cause weight gain 1
• The Endocrine Society suggests considering metformin particularly in women with cardiometabolic features such as abdominal obesity and insulin resistance 1
• Typical doses of metformin range from 1-1.5g daily, often given twice daily 2

Fertility-Specific Medications

• Clomiphene citrate is the first-line pharmacological treatment for ovulation induction in PCOS patients, with strong evidence showing approximately 80% of patients ovulate, and half who ovulate will conceive 3
• Clomiphene is significantly more effective than metformin for ovulation induction and should be tried first 3
• If clomiphene fails, use low-dose gonadotropin therapy rather than high-dose protocols to reduce ovarian hyperstimulation risk 3

Anti-Obesity Agents

• Semaglutide, a GLP-1 receptor agonist, has shown improvements in metabolic parameters and anthropometric measures in PCOS patients 2
• Liraglutide, another GLP-1 receptor agonist, has demonstrated benefits in hormonal profiles, metabolic parameters, lipids, and body composition in PCOS patients 2
• Exenatide, a GLP-1 receptor agonist, has shown hormonal and metabolic improvements when combined with metformin and lifestyle interventions in PCOS patients 2
• Orlistat, an anti-obesity agent, may help achieve weight loss and improve lipid and glucose metabolism when used in combination with COCPs and lifestyle interventions 2

Essential Treatment Algorithm

• The American College of Obstetricians and Gynecologists recommends beginning with lifestyle modification, including diet and exercise with a target of 5% weight loss, to improve both metabolic and reproductive abnormalities 1
• For metabolic/androgenic symptoms, metformin ± COCPs ± spironolactone may be used based on specific symptoms 1, 2
• For fertility, clomiphene citrate is the first-line treatment, rather than metformin 3
• For obesity, consider GLP-1 agonists or orlistat as adjuncts to lifestyle modification 2

Ovulation Induction in PCOS: Evidence‑Based Recommendations

First‑Line Pharmacologic Therapy

Adjunct Lifestyle Intervention

Role of Metformin

Safety of Metformin in Pregnancy

Metabolic Benefits Beyond Fertility

Spironolactone Use in Polycystic Ovary Syndrome: Evidence‑Based Recommendations

Initial Dosing and Titration

• Start spironolactone at 100 mg nightly for women with PCOS who are not trying to conceive; this dose provides the best balance of efficacy and tolerability. Doses may be increased to 200 mg daily if needed, but higher doses markedly raise side‑effect risk. Strength: moderate evidence from retrospective analyses. 6
• Lower starting doses (50–75 mg daily) are also effective; approximately 66 % of patients achieve clearance or marked improvement at these doses. Strength: moderate evidence. 7
• Allow several months of therapy before evaluating the full therapeutic effect, as improvement in hyperandrogenic symptoms is gradual. Strength: expert consensus. 6
• A dose of 200 mg daily is associated with a relative risk of 4.12 for menstrual irregularities compared with lower doses. Strength: moderate evidence. 6

Monitoring Requirements

• In young, healthy women with PCOS, routine potassium and renal‑function monitoring is not required; large retrospective data show only 0.75 % of potassium values exceeded 5.0 mmol/L, most of which normalized on repeat testing. Strength: moderate evidence. 6
• At‑risk patients (older age, renal/cardiovascular/hepatic disease, concurrent ACE‑I/ARB/NSAID/digoxin use, or diabetes) should have baseline and periodic potassium measurements (baseline, during therapy, after dose increases). Strength: moderate evidence. 7

Contraindications and Precautions

• Pregnancy is an absolute contraindication (Category C) because animal studies demonstrate risk of male fetal feminization; effective contraception must be ensured for all reproductive‑age women. Strength: strong (regulatory). 6
• Combined oral contraceptives (COCs) provide dual benefits of contraception and reduction of menstrual irregularities (the most common side effect, occurring in 15–30 % of patients). Strength: moderate evidence. 6
• Hormonal intrauterine devices are an alternative option for contraception and menstrual regulation. Strength: moderate evidence. 6
• Additional absolute contraindications include concurrent use of other potassium‑sparing diuretics, potassium supplements, CYP3A4 inhibitors, and combined ACE‑I + ARB therapy. Strength: moderate evidence. 8

Common Adverse Effects and Management

• Menstrual irregularities occur in 15–30 % of patients; management includes adding COCs or a hormonal IUD. Strength: moderate evidence. 6
• Dizziness reported in 3–4 % of users. Strength: moderate evidence. 9
• Headache reported in 2 % of users. Strength: moderate evidence. 7
• Patients should avoid high‑potassium foods (e.g., low‑sodium processed foods, coconut water) to minimize hyperkalemia risk. Strength: expert consensus. 7

Cancer Risk (Black‑Box Warning Clarification)

• The black‑box warning is based on animal studies using doses 100–150 × the clinical range; no human data support a carcinogenic effect. Strength: regulatory warning. 6
• Large human cohort studies (>30 million person‑years) have found no association between spironolactone use and breast, uterine, cervical, or ovarian cancers. Strength: high‑quality epidemiologic evidence. 6
• A matched cohort of 1.29 million women (8.4 million person‑years) also demonstrated no increased breast‑cancer risk with spironolactone. Strength: high‑quality epidemiologic evidence. 7
• For patients with a strong family history of breast or ovarian cancer, discuss the animal‑study warning but emphasize the reassuring human data. Strength: expert consensus. 10

Safe Drug Combinations

• Spironolactone can be safely combined with drospirenone‑containing COCs; a study of 27 women on spironolactone 100 mg + ethinyl estradiol 30 µg/drospirenone 3 mg showed no significant potassium elevation. Strength: moderate evidence. 7

Pregnancy‑Related Guidance

• Discontinue spironolactone before attempting conception because of the pregnancy contraindication. Strength: strong (regulatory). 6

Clinical Pitfalls (What to Avoid)

• Do not routinely monitor potassium in young, healthy women; it adds unnecessary cost and anxiety. Strength: moderate evidence. 6
• Do not start therapy below 50 mg daily; evidence for efficacy at very low doses is insufficient. Strength: moderate evidence. 7
• Do not prescribe spironolactone without confirming effective contraception; pregnancy risk is the most serious concern. Strength: strong (regulatory). 6
• Do not combine spironolactone with other potassium‑sparing diuretics or potassium supplements, as this poses a genuine hyperkalemia risk. Strength: moderate evidence. 8